Feed SENS
SE

Senseonics Holdings, Inc.

SENS · NASDAQ

$9.06 +1.91% (+$0.17)
1M +2.19%
Market Cap $378.7M
P/E Ratio -
Div. Yield -
ROE 165.83%

Bulios Fair Price

$9.96

9.9% upside

Current Price

$9.06

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SENS is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
28 /100
Expensive
P/B 4.19x
P/S 7.80x
EV/EBITDA N/A
Growth
100 /100
Growing
Rev. growth 29.09%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Net margin 225.34%
Op. margin 223.22%
FCF margin 199.47%
Quality
3 /100
Poor
ROE 165.83%
ROA 61.86%
Asset turnover 0.27x
Debt
55 /100
Moderate
Current ratio 6.74x
Int. coverage -20.16x
Debt/Equity 0.68x
Stability
56 /100
Moderate
Rev. volatility 28.64%
EPS volatility 24.51%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SENS
Online

About the company

Senseonics Holdings, Inc. is an American company focused on the development and manufacturing of innovative medical devices and technologies. The company specializes in the field of diabetes and has developed a revolutionary continuous glucose monitoring (CGM) system designed to help diabetes patients manage their blood glucose levels. Senseonics' CGM system allows patients to continuously monitor their glucose without the need for painful injections, improving their ability to properly manage their diabetic treatment. The company is also engaged in further research and development and follows new possibilities in diabetes care and medical technologies. Senseonics Holdings, Inc. (SENS) shares are an interesting choice for investors who follow the healthcare sector and seek investment opportunities in an innovative company that brings new solutions and improvements to diabetes patient care.

Sector

Healthcare

Industry

Medical - Devices

CEO

Timothy T. Goodnow

Employees

130

Headquarters

Germantown

Upcoming events

04 NOV

Earnings

Upcoming earnings report

48d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.